Soo-Jin Kim
Directeur Technique/Scientifique/R&D chez INOZYME PHARMA, INC.
Fortune : 2 M $ au 31/05/2024
Provenance du réseau au premier degré de Soo-Jin Kim
Entité | Type d'entité | Industrie | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 16 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Soo-Jin Kim via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder Chairman | |
ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
IVERIC BIO, INC. | Pharmaceuticals: Generic | Director/Board Member Corporate Officer/Principal | |
Novo Holdings A/S (Investment Company)
Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Financial Conglomerates | Corporate Officer/Principal | |
Nuvelution Pharma, Inc.
Nuvelution Pharma, Inc. BiotechnologyHealth Technology Nuvelution Pharma, Inc. provides solutions for R&D companies in the pharmaceutical and biotech industries. The firm leverages its knowledge, experience and relationships in the Pharma and Biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources, making this model an essential tool for pharma and biotech companies to bring products to the market. The company was founded by Sanford S. Zweifach and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Harmony Biosciences LLC
Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | Pharmaceuticals: Major | Director/Board Member | |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
VERONA PHARMA PLC | Pharmaceuticals: Major | Director/Board Member | |
The Royal College of Physicians | College/University | Corporate Officer/Principal | |
Royal College of General Practitioners
Royal College of General Practitioners Other Consumer ServicesConsumer Services The Royal College of General Practitioners is a professional membership body for family doctors in the UK and overseas. The non-profit company is based in London, UK and has subsidiaries in the United Kingdom. The British company is committed to improving patient care and clinical standards. The RCGP offers a fellowship program, which is the highest level of membership and exemplifies their motto "cum scientia caritas". The company also provides accreditation for high-quality resources and activities relevant to general practitioners. The Daffodil Standards is a free, evidence-based framework to help practices self-assess and consistently offer the best end of life and bereavement care. The RCGP represents the interests of established GPs and acts as a conduit for local matters to be raised at national meetings. | Other Consumer Services | Corporate Officer/Principal | |
KALVISTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman | |
HARMONY BIOSCIENCES HOLDINGS, INC. | Pharmaceuticals: Major | Director/Board Member | |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Medical Specialties | General Counsel | |
REATA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
COLUCID PHARMACEUTICALS INC | Biotechnology | Director/Board Member | |
MORPHIC HOLDING, INC. | Pharmaceuticals: Major | Director/Board Member | |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Biotechnology | Director/Board Member | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
Bay City Capital LLC
Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Investment Managers | Private Equity Investor | |
University of Saskatchewan | College/University | Doctorate Degree | |
DuPont Pharmaceuticals Co.
DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Pharmaceuticals: Major | Corporate Officer/Principal | |
HYPERION THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member | |
The University of Chicago Booth School of Business | College/University | Masters Business Admin | |
ACACIA PHARMA GROUP PLC | Pharmaceuticals: Other | Director/Board Member | |
Epsilon-3 Bio Ltd
Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Other | Founder | |
Thiakis Ltd.
Thiakis Ltd. Pharmaceuticals: MajorHealth Technology Thiakis Ltd. develops hormone-based treatments for obesity and other metabolic diseases. It focuses to commercialize an effective anti-obesity treatment based on a peptide hormone called oxyntomodulin. The company was founded in 2004 by Steve Bloom and John Burt and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | Biotechnology | Chief Executive Officer | |
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
The Bioindustry Association
The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012. | Miscellaneous Commercial Services | Director/Board Member | |
Scandinavian International Management Institute | College/University | Corporate Officer/Principal | |
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Tarsa Therapeutics, Inc.
Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Director/Board Member | |
RENEURON GROUP PLC | Pharmaceuticals: Major | Chief Executive Officer | |
University of Warwick | College/University | Masters Business Admin | |
The University of Manchester | College/University | Doctorate Degree | |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Chairman | |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor | |
NeRRe Therapeutics Ltd.
NeRRe Therapeutics Ltd. Medical DistributorsDistribution Services NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom. | Medical Distributors | Chairman | |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member |
Statistiques
Internationale
Etats-Unis | 26 |
Royaume-Uni | 18 |
Danemark | 6 |
Canada | 2 |
Suède | 2 |
Sectorielle
Health Technology | 37 |
Consumer Services | 8 |
Commercial Services | 4 |
Finance | 4 |
Distribution Services | 2 |
Opérationnelle
Director/Board Member | 110 |
Independent Dir/Board Member | 37 |
Corporate Officer/Principal | 27 |
Private Equity Investor | 17 |
Undergraduate Degree | 14 |
Relations les plus connectées
Insiders | |
---|---|
Ed Mathers Mathers | 47 |
Martin Edwards | 38 |
Axel Bolte | 23 |
Robert Hopfner | 20 |
Reinaldo Diaz | 17 |
Lynne Sullivan | 16 |
Kurt C. Gunter | 12 |
Doug Treco Treco | 11 |
Sanjay Subramanian | 9 |
Henric Bjarke | 8 |
Sarah Bhagat | 6 |
Matthew Winton | 5 |
David Thompson | 4 |
Gayle Gironda | 4 |
Yves Sabbagh | 3 |
- Bourse
- Insiders
- Soo-Jin Kim
- Connexions Sociétés